Dr David Chang talks to ecancer at the 2013 WIN Symposium about a translational study downstream of the "Australian Pancreatic Cancer Genome Initiative".

Results from the study found that pancreatic cancer is a very heterogeneous disease, less than 2%, which, signals the need for multiple drugs in most patients treatment regimes. The study is now looking at patients who had significant responses to treatment in order to identify potential new targets.

Filmed in Partnership with the WIN Consortium